<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234545</url>
  </required_header>
  <id_info>
    <org_study_id>F7HAEM-3850</org_study_id>
    <secondary_id>U1111-1116-2488</secondary_id>
    <nct_id>NCT01234545</nct_id>
  </id_info>
  <brief_title>Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors</brief_title>
  <official_title>A Prospective Observational Study on the Home Treatment of Haemarthrosis With rFVIIa (Activated Recombinant Factor VII) in Haemophilia A and B Patients With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy
      of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant
      human factor VII) in patients with haemophilia A and B patients with inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeds managed at home</measure>
    <time_frame>Month 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatments resulting in the control of bleeding episode</measure>
    <time_frame>within 9 hours after the first injection of study product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatments resulting in effective pain relief</measure>
    <time_frame>within 9 hours after the first injection of study product</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient/caregivers with no need of any intervention from the physician to treat the bleeding episode at home</measure>
    <time_frame>Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who used their entire treatment at home</measure>
    <time_frame>Month 8</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activated recombinant human factor VII</intervention_name>
    <description>Prescription is done at the discretion of the prescribing physician as part of normal clinical routine</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with congenital haemophilia and inhibitors to Factor VIII or IX.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with congenital haemophilia and inhibitors to factor VIII or IX

          -  Indication of activated recombinant human factor VII for the treatment of joint
             bleeding located in elbow, shoulder, wrist, hip, knee, ankle

        Exclusion Criteria:

          -  Known or suspected allergy to study product(s) or related products

          -  Clinically relevant coagulation disorders other than congenital haemophilia A or B
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Algiers</city>
        <zip>16035</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casablanca</city>
        <zip>20000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riyadh</city>
        <zip>3542</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Morocco</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

